Business Wire

Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, ...
JSTOR Daily

Hemispheric Asymmetry as Indexed by Differences in Direction of Initial Conjugate Lateral Eye-Movements (CLEMs) in Response to Verbal, Spatial, and Emotional Tasks

Following previous research showing frequency and direction of conjugate lateral eye-movements (CLEMs) to be a valid indicator of hemispheric asymmetry (Schwartz, Davidson, & Maer, 1975), the purpose ...
JSTOR Daily

ECM Algorithms That Converge at the Rate of EM

We show that the ECM algorithm can always be constructed to converge at the same or approximately the same rate as the EM algorithm. The construction is based on the well-known conjugate directions ...
Nasdaq

Merck Reports Positive Results From Two Trials Of V114 Phase 3 Pediatric Clinical Program

(RTTNews) - Merck & Co., Inc. (MRK) announced Thursday positive topline results from the two trials of the V114 Phase 3 pediatric clinical program. The company noted that V114, the investigational ...